ArticleLangenbeck's archives of surgery2025
Complications following upfront pancreatectomy with venous resection do not compromise adjuvant chemotherapy delivery and survival in pancreatic cancer.
Article in Langenbeck's archives of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe combined burden of vascular resections and pancreas-specific complications may preclude or delay adjuvant chemotherapy and impair survival. We evaluated the effect of complications on adjuvant therapy delivery and survival after upfront pancreatectomy with venous resection (PVR).
methodsPatients undergoing upfront PVR were retrieved from a prospectively maintained database at two high-volume Institutions. The incidence and severity of complications were correlated with administration of adjuvant chemotherapy and overall survival.
resultsOverall, 280 patients underwent upfront PVR. 75% (N = 210) underwent pancreatoduodenectomy (PD), 15% (N = 41) distal pancreatectomy (DP), and 10% (N = 29) total pancreatectomy (TP). Major morbidity occurred in 34% (N = 96), with 4% (N = 12) 90-day mortality. Overall rates of POPF, PPH, and DGE were 22%, 15%, and 18%, respectively. Mortality was higher in Type IV venous resections (14%, p = 0.028). DP was associated with higher morbidity but similar mortality compared to PD and TP. The only factor independently associated with adjuvant chemotherapy delivery, administered in 196 (70%), was ASA score < 3 (p = 0.003). Factors independently associated to worse OS were age > 75 years, TP, pT > 2, pN2, and lack of adjuvant chemotherapy delivery.
conclusionsUpfront PVR has an acceptable risk profile and oncologic outcomes when adjuvant chemotherapy is administered. Survival and the delivery of adjuvant therapy do not appear to be negatively affected by complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.